D

Duke University Health System | Duke Gastroenterology Clinic - Clinic 2

Research site

(Unclaimed)

Location

40 Medicine Circle, orange zone basement Rm 0341, Durham, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Ifinatamab

Linvoseltamab

Lurbinectedin

Topotecan

Amrubicin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Active, not recruiting

Small Cell Lung Cancer

Drug: Topotecan

Drug: Amrubicin

Locations recently updated

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed...

Enrolling

Multiple Myeloma

Drug: Linvoseltamab

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that tar...

Enrolling

Relapsed/Refractory Multiple Myeloma

Biological: CB-011

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics...

Active, not recruiting

Extensive-stage Small-cell Lung Cancer

Drug: Ifinatamab Deruxtecan (I-DXd)

Trial sponsors

C

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms